EP4, being a common target on both tumor and host cells contributing to tumor-associated lymphangiogenesis, reaffirms the therapeutic value of EP4 antagonists in the intervention of lymphatic metastasis in breast cancer. This evidence concerns the gene PTGER4 and breast carcinoma.